{"text": ["The", "Extreme", "Risks", "of", "Trading", "Your", "Own", "Retirement", "Assets", "-", "January", "14,", "2020"], "created_at": "2020-01-14 19:23:07"}
{"text": ["AbbVie", "Inc.", "--", "Moody's", "announces", "completion", "of", "a", "periodic", "review", "of", "ratings", "of", "AbbVie", "Inc."], "created_at": "2020-01-14 18:01:22"}
{"text": ["New", "Head-to-Head", "Phase", "3", "Data", "Show", "SKYRIZI\u2122", "(risankizumab)", "Superior", "to", "Cosentyx\u00ae", "(secukinumab)", "Across", "Primary", "and", "All", "Ranked", "Secondary", "Endpoints", "in", "Adults", "with", "Moderate", "to", "Severe", "Plaque", "Psoriasis", "at", "52", "Weeks"], "created_at": "2020-01-14 13:45:00"}
{"text": ["AbbVie's", "MAVIRET\u00ae", "now", "listed", "on", "the", "Newfoundland", "and", "Labrador", "formulary"], "created_at": "2020-01-14 10:30:00"}
